You are here:

tafamidis meglumine (Vyndaqel)

Advice

in the absence of a submission from the holder of the marketing authorisation:

tafamidis meglumine (Vyndaqel®) is not recommended for use within NHS Scotland.

Indication under review: treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment,

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: tafamidis meglumine (Vyndaqel)
SMC Drug ID: 877/13
Manufacturer: Pfizer Ltd
Indication: Treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment.
BNF Category:
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 13 May 2013

Back